Oxalate Degrading Lactic Acid Bacteria in Prevention and Management of Kidney Stone

 

Abstract

Oxalate degrading lactic acid bacteria possessing oxc (Oxalyl-CoA decarboxylase) and frc (Formyl-CoA transferase) genes are now being explored for their application as ingredients for prevention and management of kidney stone. Kidney stones increase the risk of developing chronic kidney disease and is associated with dysbiosis of gut microbiota Vaziri et al. [1]. Probiotics enhances the gut barrier by increasing mucus integrity, epithelial tight junction (ETJ) and epithelial cells survival and also control the overgrowth of pathobionts by reduction of pH and production of antimicrobial peptides (AMPs). Probiotic bacteria belonging to Bifidobacterium and Lactobacillus have been studied for their potential capability of oxalate degradation potential and reported high and efficient degradation of intestinal oxalate and reduces the level of oxaluria in patients with calcium-oxalate kidney stone and mild hyperoxaluria. The key oxalate degrading genes Oxc and frc have been sequenced in Lactobacillus and Bifidobacterium spp. and these strains are commonly used in dairy for probiotic preparation and management of kidney stone and are generally recognised as safe for human consumption. It was demonstrated that oxalate degrading Lactobacillus and Bifidobacterium species possessing probiotic properties and could possibly be used in a prophylactic approach and natural way for prevention and management of kidney stone disease.

Read more about this article: https://lupinepublishers.com/complementary-alternative-medicine-journal/fulltext/oxalate-degrading-lactic-acid-bacteria-in-prevention-and-management-of-kidney-stone.ID.000172.php

Read more Lupine Publishers Google Scholar Articles :   https://scholar.google.com/citations?view_op=view_citation&hl=en&user=0sWAIssAAAAJ&citation_for_view=0sWAIssAAAAJ:UxriW0iASnsC

Modulating Serum Lipids with Berberine in Naturopathic Clinical Practice

 

Abstract

Medical intervention to reduce the risk of atherosclerosis using lipid modulating medications has been a target for reducing cardiovascular risk for over 40 years. Lipid lowering medications, HMG-CoA reductase inhibitors (Statin’s), and more recently PCSK9 inhibitors (PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are now and in the future will be the main stay therapy for reducing Atherosclerosis. However, the uncertainty of statin induced myalgia and other bad publicity via the media and internet reports has caused many patients to opt out of statin therapy. Berberine and is quinoline alkaloid has had several clinical trials demonstrating potential in managing cardiovascular disease risk. Berberine is a safe and natural alternative for modulating circulating lipids including LDL-C, however possible drug interactions, due to its effects on P450 enzymes, does indicate some caution should be exercised.

Read more about this article: https://lupinepublishers.com/complementary-alternative-medicine-journal/fulltext/modulating-serum-lipids-with-berberine-in-naturopathic-clinical-practice.ID.000171.php

Read more Lupine Publishers Google Scholar Articles :   https://scholar.google.com/citations?view_op=view_citation&hl=en&user=0sWAIssAAAAJ&citation_for_view=0sWAIssAAAAJ:dshw04ExmUIC